All In Biotech

Drug Trial Radar · NCT05888922

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Oct 17, 2024

Primary completion

Oct 2026

Study completion Nov 16, 2026

Sponsor

Sponsor type
Industry
Collaborators
Bioskin GmbH; Astrum CRO, S.L.
First posted
Jun 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss). Approximately 520 women is planned to take part in the study. Participants will be randomly assigned to receive either oral minoxidil, topical minoxidil 2% solution, or placebo. Neither the participants nor the study staff will know which treatment has been assigned. The study will last up to 36 weeks, including a treatment period of 24 weeks and a follow-up period. Participants will attend regular study visits to assess hair growth and monitor safety. Site investigators will evaluate changes in hair growth and hair density using scalp imaging, investigator assessments, and participant questionnaires. Safety will be monitored through physical examinations, vital signs, laboratory tests, electrocardiograms, and the recording of side effects throughout the study.

Conditions

  • Androgenetic Alopecia
  • Female Pattern Baldness

Interventions

  • Minoxidil TabletsDrug

    The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

  • Minoxidil TopicalDrug

    The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

  • Placebo oral tabletDrug

    The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

  • Vehicle solutionDrug

    The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Target Area non vellus Hair Counts (TAHC)Time frame: From baseline to week 24

Locations

27 sites in 4 countries. Site status is shown where the registry gives one.

  • Fachklinik Bad Bentheim Klinisches Studienzentrum

    Bad Bentheim, Germany

  • CRC - Charité Universitätsmedizin Berlin Clinical Research Center for Hair and Skin Science

    Berlin, Germany

  • emovis by Futuremeds GmbH

    Berlin, Germany

  • Klinische Forschung Berlin Mitte GmbH

    Berlin, Germany

  • Hautzentrum im Jahrhunderthaus

    Bochum, Germany

  • Rosenpark Reasearch GmbH

    Darmstadt, Germany

  • Klinische Forschung Dresden GmbH

    Dresden, Germany

  • Privatpraxis Dr. Hilton & Partner

    Düsseldorf, Germany

  • Klinik für Dermatologie, Venerologie und Allergologie - Universitätsmedizin Frankfurt

    Frankfurt, Germany

  • Dermaticum - Privatpraxis für Dermatologie

    Freiburg im Breisgau, Germany

  • Eurofins bioskin - Research Center Dermatology

    Hamburg, Germany

  • Klinische Forschung Hamburg GmbH

    Hamburg, Germany

  • Klinische Forschung Hannover Mitte GmbH

    Hanover, Germany

  • Klinische Forschung Karlsruhe GmbH

    Karlsruhe, Germany

  • Siteworks - Zentrum für klinische Studien Karslruhe

    Karlsruhe, Germany

  • Siteworks - Prüfzentrum Lohne

    Löhne, Germany

  • Haut-und Lasercentrum - Dr. Tanja Fischer und Kollegen

    Potsdam, Germany

  • SGS proderm GmbH

    Schenefeld, Germany

  • Klinische Forschung Schwerin Gmb

    Schwerin, Germany

  • TRIDERM Study Site Dermatological practice Dr. Leitz and colleagues

    Stuttgart, Germany

  • Università Sapienza di Roma Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari U.O.C. di Dermatologia Centro per lo studio sulla fisiopatologia degli Annessi Cutanei Sapienza Università di Roma

    Roma, Italy

  • Hospital CUF Descobertas - Ensaios Clínicos

    Lisbon, Portugal

  • Personal Derma - Clínica Dermatológica & Estética

    Lisbon, Portugal

  • Instituto Dermatológico da Madeira - Dermatologia e Laserterapia

    Madeirã, Portugal

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Clínica Grupo Pedro Jaén

    Madrid, Spain

  • Institut Medico Ricart (IMR)

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.